The Last Analogue Discipline in Modern Medicine
Clinical pathology has been the last major medical discipline to transition from analogue to digital primary diagnosis. Radiology completed its transition to digital image acquisition and display in the 1990s and 2000s, driven by the commercial availability of digital X-ray, CT, and MRI systems whose digital output enabled picture archiving and communication systems that transformed the operational efficiency of radiology departments. Cardiology digitalised its rhythm recording and echocardiography. Even ophthalmology digitalised its fundus imaging. Pathology, whose primary diagnostic tool is the microscope, remained anchored to physical glass slides carrying tissue sections stained with haematoxylin and eosin or immunohistochemical markers, examined by pathologists through optical microscopes whose magnification, field of view, and illumination the pathologist controls manually as they form a diagnostic impression from the tissue morphology visible in the slide. The physical slide required physical presence at a microscope, physical transport between sites for second opinion consultations, physical archiving in space-consuming slide libraries, and the attention of a pathologist whose time and geographic availability determined the throughput and turnaround time of the diagnostic process.
Digital pathology whole slide imaging scanners acquire complete digital images of stained tissue sections at multiple magnifications, creating gigapixel image files whose information content matches that of the physical slide and whose digital format enables the storage, transmission, viewing, and computational analysis capabilities that the physical slide cannot support. The whole slide image can be viewed on a diagnostic workstation by a pathologist anywhere in the world with network access to the image server, enabling remote second opinion consultation, subspecialty referral, and the telepathology services that allow pathologists at central reporting centres to support clinical laboratories at sites where pathologist recruitment is difficult. The regulatory approval of whole slide imaging for primary diagnosis in the United States, granted by the FDA in 2017 for specific scanner models and validated for specific diagnostic applications, removed the principal regulatory barrier to the adoption of digital pathology as the primary diagnostic workflow in US hospital pathology laboratories.
Whole Slide Imaging Technology and Its Clinical Implementation
The commercial whole slide imaging scanners that have driven digital pathology adoption are precision optical instruments whose scanning speed, image quality, and reliability must meet the operational demands of a clinical pathology laboratory processing hundreds of slides daily without the quality failures or downtime that would delay patient diagnosis. The scanning technology uses high-resolution objective lenses, automated focus systems that maintain image sharpness across the depth variations of tissue sections whose thickness and flatness are not perfectly uniform, and high-throughput slide loading mechanisms that allow batch scanning of full cassettes of slides without manual intervention between scans. The image files produced by whole slide scanning at twenty-times and forty-times magnification, the magnifications most commonly used for diagnostic pathology, are typically two to five gigabytes per slide at twenty-times and up to ten gigabytes per slide at forty-times magnification, creating storage and network bandwidth requirements that have driven significant investment in digital pathology IT infrastructure by hospital systems adopting digital primary diagnosis workflows.
The artificial intelligence applications that whole slide images enable represent the commercial frontier of digital pathology whose development has attracted the most significant investment from the technology and pharmaceutical sectors over the past five years. AI-based image analysis algorithms that detect specific pathological features, quantify immunohistochemical marker expression, classify tissue samples by tumour grade or molecular subtype, and provide the computational pathology outputs that human pathologists cannot generate from manual glass slide review are creating a new commercial layer in the digital pathology market whose revenue potential may ultimately exceed that of the scanner and image management infrastructure on which it depends. Pharmaceutical companies whose clinical trial biomarker analysis and companion diagnostic development depend on the standardised, quantitative tissue analysis that computational pathology enables are among the most commercially significant customers for digital pathology AI applications, creating a pharmaceutical market demand that complements the clinical laboratory market demand for diagnostic AI that improves pathology workflow efficiency and diagnostic consistency.
Top 10 Companies in Digital Pathology Globally
- Philips: IntelliSite Pathology Solution is the FDA-cleared digital pathology platform most widely deployed for primary diagnosis in the US; its integrated scanner, image management software, and pathology workflow optimisation tools create the complete digital pathology infrastructure that hospital systems adopting primary digital diagnosis require, and its enterprise health informatics integration creates the data connectivity that digital pathology requires to function within existing hospital information system architectures.
- Leica Biosystems (Danaher): Aperio whole slide imaging scanner family is the most widely installed WSI platform in research and clinical pathology globally; its Aperio GT 450 high-throughput scanner and Aperio LV1 live image scanner and its eSlide image management platform create the complete digital pathology infrastructure whose installed base in academic and pharmaceutical research pathology is the largest of any single vendor.
- Hamamatsu Photonics: Japanese photonics company whose NanoZoomer whole slide imaging platform is widely used in pharmaceutical and academic research pathology; its image acquisition performance and its reputation in the scientific imaging market create the research pathology position from which clinical laboratory adoption is developing as whole slide imaging extends from research to routine diagnostic use.
- 3DHISTECH: Hungarian digital pathology company with the Pannoramic scanner family and CaseCenter image management platform; its price-competitive scanner portfolio and its European market focus create the digital pathology adoption pathway for European hospital laboratories whose procurement budgets are more constrained than the US academic medical centres where premium scanner platforms have been adopted earliest.
- PathAI: US computational pathology company developing AI algorithms for disease detection, biomarker quantification, and clinical trial endpoint assessment; its pharmaceutical company partnerships for clinical trial pathology and its AISight pathology AI platform create the commercial AI pathology business whose pharmaceutical market revenue supplements the clinical laboratory AI diagnostic market that regulatory approval processes are more slowly creating.
- Paige: US digital pathology AI company with the first FDA-approved AI for prostate cancer pathology detection; its regulatory approval creates the commercial precedent that AI-assisted pathology diagnosis requires to move from research applications into clinical reimbursement, and its collaboration with Microsoft for the development of universal pathology AI models creates the technology partnership that its commercial development requires at the frontier of foundation model pathology AI.
- Roche Diagnostics: Diagnostic company with NAVIFY Digital Pathology platform integrating WSI with tissue biomarker analysis and the companion diagnostic development expertise whose pharmaceutical business creates; its VENTANA staining platform and its digital pathology integration create the tissue-to-diagnosis workflow that combines staining, scanning, and image analysis in a single vendor relationship that simplifies laboratory procurement.
- Grundium: Finnish whole slide imaging company with portable and compact WSI scanners for smaller laboratory environments; its Ocus scanner range whose portability and lower price point relative to high-throughput clinical scanners creates the digital pathology entry point for district hospitals and smaller clinical laboratories whose slide volumes do not justify the investment in high-throughput scanning infrastructure.
- Aignostics: German computational pathology company developing tissue-based biomarker AI for pharmaceutical research and clinical diagnostics; its foundation model approach to pathology image analysis and its partnerships with European academic pathology institutions create the European computational pathology capability that pharmaceutical companies conducting clinical trials in European patient populations need for standardised tissue biomarker analysis.
- Sectra: Swedish medical imaging IT company whose PACS and image management solutions extend to digital pathology image management and integration; its radiology and pathology image management integration creates the unified diagnostic imaging infrastructure that hospital systems whose radiology is already fully digital can extend to pathology without the separate IT infrastructure that standalone digital pathology image management requires.
The AI Layer and the Pharmaceutical Market
The artificial intelligence applications that whole slide images enable are attracting investment from pharmaceutical companies whose clinical trial biomarker analysis requires the standardised quantitative tissue assessment that computational pathology provides. AI algorithms that detect residual tumour after neoadjuvant therapy, quantify PD-L1 and other immunotherapy biomarker expression, and classify tumour microenvironment composition from whole slide images are creating the regulatory-grade companion diagnostic infrastructure that precision oncology drug development requires. The FDA’s qualification of digital pathology endpoints for regulatory submission and the EMA’s guidance on AI-assisted pathology in clinical trial biomarker assessment are creating the regulatory pathway that pharmaceutical company investment in computational pathology AI is following. The commercial consequence is a pharmaceutical services market for computational pathology whose revenue potential among the oncology drug developers running tissue biomarker trials is substantial and whose growth rate reflects the pace at which targeted therapy and immunotherapy approvals are making tissue biomarker assessment a standard component of clinical trial design.